+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ankylosing Spondylitis Market - Global Forecast 2026-2032- Product Image
Ankylosing Spondylitis Market - Global Forecast 2026-2032- Product Image
New

Ankylosing Spondylitis Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5292911
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The ankylosing spondylitis market is evolving, marked by increased innovation, shifting payer expectations, and a stronger emphasis on integrated patient-centric care models. Senior decision-makers face complex dynamics requiring agile strategies and data-driven insights to maintain a competitive edge.

Ankylosing Spondylitis Market Snapshot

The ankylosing spondylitis market witnessed significant expansion from USD 6.04 billion in 2025 to USD 6.51 billion in 2026, with continued growth anticipated at a CAGR of 8.67%—reaching USD 10.81 billion by 2032. Growing demand for advanced therapies, digital health solutions, and payer-driven care models is actively shaping procurement and commercialization strategies. Strategic investments are being made to accommodate evolving clinical paradigms and optimize stakeholder value, as industry leaders focus on ensuring greater patient access and outcomes.

Scope & Segmentation

  • Therapeutic Classes: Biologics, targeted small molecules, and adjunctive therapies are increasingly tailored to improve patient outcomes and provide differentiated clinical value.
  • Administration Route: Injectable (intravenous, subcutaneous), oral (tablet, capsule, solution), and topical (cream, gel) formulations influence patient adherence, operational logistics, and provider workflows across delivery settings.
  • Age Cohorts: Distinct treatment approaches and safety requirements are established for adults, geriatric, and pediatric populations, requiring unique labeling and care planning for each group.
  • Care Settings: Homecare centers, hospitals, and specialty clinics present variable adoption patterns and operational considerations, affecting both the efficiency of service delivery and market penetration strategies.
  • Geographical Regions: Demand and deployment are shaped by regulatory trends, payer criteria, and infrastructure disparities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. Diverse policies and access requirements drive differentiated go-to-market models.
  • Technologies: Digital health platforms, remote monitoring, and telemedicine enhance adaptive disease management and broaden patient engagement, supporting expanded monitoring, data integration, and flexible follow-up solutions.

Key Takeaways

  • Novel therapeutic development is expanding, with stakeholder priorities shifting toward demonstrating real-world clinical and value-based outcomes.
  • Emergent digital health tools, including telehealth, are modernizing patient monitoring, supporting sustained adherence, and streamlining provider follow-up activities.
  • Increased investment in pragmatic and outcomes-focused clinical trials responds to payer and regulatory expectations, demanding robust evidence strategies for market access.
  • Segmenting products by administration method, patient demographics, and care environment enables targeted provider training, higher patient support, and optimized supply planning.
  • Resilient manufacturing and adapted supply chains are essential as external pressures require companies to shift sourcing, logistics, and production to mitigate risk and cost volatility.
  • Strategic collaboration among pharma companies, CROs, and digital health providers is reducing time to market and actively managing patient engagement, adherence, and continuous monitoring gaps.

Tariff Impact: Navigating Policy Shifts in 2025

New tariff measures introduced in 2025 are altering procurement and supply chain decisions, requiring manufacturers to reassess supplier relationships and production networks. To offset cost pressures and boost supply reliability, firms are pursuing rigorous margin management, targeted localization of production, and updated supplier contracts. Healthcare buyers and providers are adapting purchasing practices to reconcile value and affordability, highlighting the need for robust scenario analysis, cross-functional coordination, and ongoing risk assessment.

Methodology & Data Sources

This market intelligence is grounded in a mixed-methods research approach, incorporating primary interviews with senior clinicians, payers, and supply chain executives, reinforced by secondary analysis of peer-reviewed publications and policy documentation. Strict thematic coding and quality control processes ensure all insights meet industry standards for accuracy, relevance, and confidentiality.

Why This Report Matters

  • Delivers actionable strategies for responding to dynamic clinical, regulatory, and operational landscapes, fortifying competitive market position and enabling evidence-based leadership.
  • Maps key market trends and stakeholder dynamics across diverse geographies and emerging health technologies, supporting data-driven portfolio management and investment initiatives.
  • Offers clear guidance on market access planning, supply chain resilience, and strategic partnerships tailored for executives overseeing complex healthcare portfolios.

Conclusion

To succeed in the ankylosing spondylitis market, executives must balance clinical innovation, operational adaptability, and integrated access strategies. Aligning organizational capabilities to address payer requirements and evolving patient needs will support sustainable growth and maximize long-term market value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Ankylosing Spondylitis Market, by Administration Route
8.1. Injectable
8.1.1. Intravenous Infusion
8.1.2. Subcutaneous Injection
8.2. Intravenous
8.3. Oral
8.3.1. Capsules
8.3.2. Tablets
9. Ankylosing Spondylitis Market, by Patient Age Group
9.1. Adult
9.2. Geriatric
9.3. Pediatric
10. Ankylosing Spondylitis Market, by End User
10.1. Homecare Centers
10.2. Hospitals
10.3. Specialty Clinics
11. Ankylosing Spondylitis Market, by Route Of Administration
11.1. Injectable
11.1.1. Intravenous Infusion
11.1.2. Subcutaneous Injection
11.2. Oral
11.2.1. Solutions
11.2.2. Tablets
11.3. Topical
11.3.1. Creams
11.3.2. Gels
12. Ankylosing Spondylitis Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Ankylosing Spondylitis Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Ankylosing Spondylitis Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Ankylosing Spondylitis Market
16. China Ankylosing Spondylitis Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. Amgen Inc.
17.7. Biothera Pharmaceuticals, Inc.
17.8. Boehringer Ingelheim International GmbH
17.9. Bristol-Myers Squibb Company
17.10. Celgene Corporation
17.11. Celltrion Healthcare Co.,Ltd.
17.12. Eisai Co., Ltd
17.13. Eli Lilly and Company
17.14. Gilead Sciences, Inc.
17.15. GlaxoSmithKline PLC
17.16. Hetero Drugs Limited
17.17. Johnson & Johnson Services Inc.
17.18. Merck & Co. Inc.
17.19. Mylab Discovery Solutions Pvt. Ltd.
17.20. Novartis AG
17.21. Pfizer, Inc.
17.22. Reliance Life Sciences
17.23. Samsung Bioepis Co., Ltd.
17.24. Sandoz International GmbH
17.25. Shanghai Pharmaceuticals Holding Co., Ltd.
17.26. Takeda Pharmaceutical Company Limited
17.27. Trinity Biotech PLC
17.28. UCB, Inc.
17.29. Xian Janssen Pharmaceutical Ltd
List of Figures
FIGURE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 118. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 120. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 121. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 122. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 123. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 126. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 127. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 138. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 140. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 141. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 142. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 143. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 146. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 147. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 159. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 161. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 162. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 163. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 164. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 167. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 168. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 169. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 171. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 172. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 173. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 174. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 177. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 178. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 189. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 191. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 192. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 193. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 194. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 197. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 198. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 199. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 200. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 201. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 202. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 203. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 204. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 206. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 207. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 208. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 209. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 210. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 211. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 212. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 213. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 214. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 217. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 218. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 219. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 230. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 231. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 232. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 233. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 234. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 235. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 238. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 239. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Ankylosing Spondylitis market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Biothera Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celltrion Healthcare Co.,Ltd.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hetero Drugs Limited
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Trinity Biotech PLC
  • UCB, Inc.
  • Xian Janssen Pharmaceutical Ltd

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.51 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.81 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Ankylosing Spondylitis Market Report 2025 - Product Image

Ankylosing Spondylitis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ankylosing Spondylitis Market Forecast to 2033 - Product Image

Ankylosing Spondylitis Market Forecast to 2033

  • Report
  • 150 Pages
  • Global
From
Ankylosing Spondylitis - Global Strategic Business Report - Product Image

Ankylosing Spondylitis - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Ankylosing Spondylitis - Pipeline Insight, 2025 - Product Image

Ankylosing Spondylitis - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From

About the Ankylosing Spondylitis Drug Market

The Ankylosing Spondylitis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Ankylosing Spondylitis is a chronic inflammatory disorder that affects the spine and other joints, and is characterized by pain and stiffness. Ankylosing Spondylitis Drugs are used to reduce inflammation and pain, and to improve mobility. These drugs are typically administered orally or by injection, and may include biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The Ankylosing Spondylitis Drug market is highly competitive, with a number of large pharmaceutical companies offering products. Some of the major players in the market include AbbVie, Amgen, Pfizer, Janssen, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.